{"ticker": {"uuid": "af453eff-9ece-4638-b97f-ba7e51b3560a", "symbol": "SANA", "name": "Sana Biotechnology Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/sana-biotechnology-sana-publishes-14-211145927.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T21:11:45+00:00", "published_display": "16 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in Focus - Tick Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPbU9EZjJmVzlzWENWTFdnOWZxS1VpQUN0S1dPYTUyNjRfdUZSUG1ORXp4VFdOa2djaGd5RHlWWHVoTndPZDdycXlBWmdQaDV0R0JsWFRQTDFuc1kwbTIxOEJ2UUg2Rzl0cVNVdkRDMjRRNWVCb1I5cjU3aWdUOUVIR0I1aW01MUx3aU5udXdqc0R0UGVsc2Q3QmRRZ1Z1TFMxakxESlhvWDY3SGNweWtsUW9wSVAydVNmOGtLZERKdTNZSllvNUpveWxCNk5JQkZHbGdnbg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T16:40:15+00:00", "published_display": "15 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes", "summary": "Sana Biotechnology announced a follow-on publication in The New England Journal of Medicine (NEJM) detailing 14-month follow-up data from an investigator-sponsored study of UP421, a hypoimmune-modified islet cell therapy for Type 1 Diabetes. The data reinforces that HIP-modified ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326134/0/en/sana-biotechnology-announces-follow-on-publication-in-the-new-england-journal-of-medicine-nejm-highlighting-groundbreaking-long-term-data-and-durability-of-hypoimmune-modified-isle.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T22:11:59", "published_display": "13 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Morgan Stanley 23rd Annual Global Healthcare Conference summary", "summary": "Sana Biotechnology (SANA) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, outlining its strategic vision to revolutionize medicine through gene and cell-based therapies, specifically targeting allogeneic transplant rejection and precise genetic repair. T", "url": "https://quartr.com/events/sana-biotechnology-inc-sana-morgan-stanley-23rd-annual-global-healthcare-conference_FkPpRoH0", "source_name": "Quartr", "published_at": "2026-07-08T21:10:48", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary", "summary": "Sana Biotechnology presented key scientific advances and clinical data at the 43rd Annual J.P. Morgan Healthcare Conference 2025, highlighting the first successful transplant of gene-edited allogeneic islet cells in a type 1 diabetes patient without immunosuppression. The company", "url": "https://quartr.com/events/sana-biotechnology-inc-sana-43rd-annual-j-p-morgan-healthcare-conference-2025_FkPpRpPu", "source_name": "Quartr", "published_at": "2026-07-08T21:10:48", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed", "summary": "Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, including the Russell 3000 Value and Russell 2000 Value indexes. This removal impacts how index funds and institutional investors view the stock, but it doesn't change the company's scientific o", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sana/sana-biotechnology/news/sana-biotechnology-sana-is-up-181-after-removal-from-key-rus", "source_name": "Simply Wall Street", "published_at": "2026-07-08T20:07:13", "published_display": "08 Jul 2026 20:07", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotech heads to EASD with diabetes cell therapy update", "summary": "Sana Biotechnology will present clinical findings from its first-in-human study of UP421 at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This experimental cell therapy is designed to make transplanted insulin-producing cells \"hidden\" from the imm", "url": "https://longevity.technology/news/sana-biotech-heads-to-easd-with-diabetes-cell-therapy-update/", "source_name": "Longevity.Technology", "published_at": "2026-07-08T14:39:13", "published_display": "08 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Bank of America Global Healthcare Conference 2026 Summary", "summary": "Sana Biotechnology (SANA) delivered a summary at the Bank of America Global Healthcare Conference 2026, highlighting its dual strategic focus on engineering cells both ex vivo (for cell replacement in Type 1 diabetes) and in vivo (for cell repair/signaling change in CAR-T therapy", "url": "https://quartr.com/events/sana-biotechnology-sana-bank-of-america-global-healthcare-conference-2026_FkPpTd0w", "source_name": "Quartr", "published_at": "2026-07-08T08:41:05", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar", "summary": "This document from Sana Biotechnology details a Statement of changes in beneficial ownership of securities for Director Bishop Hans Edgar. The filing is a routine disclosure of insider transactions as required by the SEC.", "url": "https://www.moomoo.com/news/notice/307681675/sana-biotechnology-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-08T04:11:24", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Sana Biotechnology Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Sana Biotechnology Inc. on July 7, 2026, as published by Investing.com. It is a brief announcement indicating an insider transaction or change in beneficial ownership for the company. The article contains minimal detail beyond the initi", "url": "https://ng.investing.com/news/stock-market-news/form-4-sana-biotechnology-inc-for-7-july-93CH-2589772", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T20:39:13", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares", "summary": "Sana Biotechnology director Hans Edgar Bishop received 6,297 fully vested restricted stock units (RSUs) as a compensation-related grant, increasing his direct holdings to 5,854,800 shares. The Form 4 filing indicates this was a stock grant at a price of $0.00 per share, not an op", "url": "https://www.stocktitan.net/sec-filings/SANA/form-4-sana-biotechnology-inc-insider-trading-activity-750821490b89.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:24", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?", "summary": "Sana Biotechnology (SANA) was recently removed from several Russell value-oriented benchmarks, including the Russell 2000, which could impact its institutional investor base and liquidity. Despite potential short-term pressure, the article suggests that the company's clinical mil", "url": "https://www.sahmcapital.com/news/content/will-removal-from-russell-value-benchmarks-change-sana-biotechnologys-sana-institutional-investor-narrative-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T07:39:35", "published_display": "03 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025", "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ:SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana made false statements and concealed risks regarding its financial ca", "url": "https://www.natlawreview.com/press-releases/sana-lawsuit-alert-levi-korsinsky-notifies-sana-biotechnology-inc-0", "source_name": "The National Law Review", "published_at": "2026-07-02T18:41:21", "published_display": "02 Jul 2026 18:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026", "summary": "Sana Biotechnology will present clinical data at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight results from a first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune", "url": "https://finance.yahoo.com/healthcare/articles/sana-biotechnology-announces-symposium-presentation-130000389.html", "source_name": "Market source", "published_at": "2026-07-02T07:41:25", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana to show first-in-human islet transplant data without immunosuppression", "summary": "Sana Biotechnology (NASDAQ: SANA) is set to present clinical data on UP421, an allogeneic primary islet cell therapy utilizing its hypoimmune platform, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This first-in-human transplant data for type 1", "url": "https://www.stocktitan.net/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-u6x9m1r88pgo.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:43", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Symposium Presentation at the", "summary": "Sana Biotechnology, Inc. (NASDAQ: SANA) announced a symposium presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight clinical data from a first-in-human study of UP421, an allogeneic primary islet cell therap", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320655/0/en/sana-biotechnology-announces-symposium-presentation-at-the-european-association-for-the-study-of-diabetes-easd-annual-meeting-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T12:40:33", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Sana Biotechnology stock rating on IND filing", "summary": "Citizens has reiterated a Market Outperform rating and an $8.00 price target for Sana Biotechnology (NASDAQ:SANA) following the company's plans to file an Investigational New Drug application for SG293, their first fusogen-based in vivo CAR-T program. Although the stock currently", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-sana-biotechnology-stock-rating-on-ind-filing-93CH-4769771", "source_name": "Investing.com", "published_at": "2026-07-01T09:40:33", "published_display": "01 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark", "summary": "Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 3000 Value Benchmark. This news follows several other index removals for the company, including the Russell Small Cap Comp Value Benchmark, Russell 2500 Value Benchmark, and Russell 2000 Value Benchmark. ", "url": "https://www.marketscreener.com/news/sana-biotechnology-inc-nasdaqgs-sana-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8cf320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:10:21", "published_display": "29 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark", "summary": "Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 2500 Value Benchmark. This news comes amidst several other recent announcements regarding the company's removal from various Russell indices and presentations at healthcare conferences, as well as an equi", "url": "https://www.marketscreener.com/news/sana-biotechnology-inc-nasdaqgs-sana-dropped-from-russell-2500-value-benchmark-ce7f5fdcd88fff20", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:10:44", "published_display": "29 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025", "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) seeking to recover losses for shareholders who purchased shares between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana Biotechnology made false s", "url": "https://natlawreview.com/press-releases/join-class-action-recover-losses-sana-biotechnology-inc-sana-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T05:10:44", "published_display": "28 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana overstated its financial capacity and the prospects of certain produ", "url": "https://natlawreview.com/press-releases/lost-money-sana-biotechnology-inc-sana-contact-levi-korsinsky-join-class", "source_name": "The National Law Review", "published_at": "2026-06-27T15:10:14", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sana Biotechnology, Inc. \u2013 NASDAQ:SANA", "summary": "This page from TradingView displays financial information for Sana Biotechnology, Inc. (NASDAQ: SANA), specifically focusing on its price-to-earnings forward metric. The content indicates that the company's market data is closed with no trades. The article is a financial data pag", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:14", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sana Biotechnology, Inc. \u2013 NASDAQ:SANA", "summary": "This article provides the enterprise value to EBIT forward for Sana Biotechnology, Inc. (NASDAQ: SANA). It presents financial data via TradingView, indicating no current trades and a closed market for the stock. The content primarily focuses on the financial metric for SANA.", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:46", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA)", "summary": "This article provides an overview of Sana Biotechnology, Inc. (NASDAQ:SANA)'s financial actuals and estimates. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and analyst forecasts for future price target", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:00", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SANA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Sana Biotechnology, Inc. (SANA) stock, including current price, analyst ratings, and historical performance. Analysts project a max estimate of $16.00 and a min estimate of $7.00 for SANA, with a current price of $3.26. The company's financials", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:51", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Sana Biotechnology Inc's (SANA) dividends and stock splits. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock prices and market capit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sana/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:10", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Sana Biotechnology Inc (SANA), including analyst ratings, price targets, and EPS estimates. Based on 9 analysts, the stock has a \"Buy\" rating with a target price of $7.00, representing a significant upside. The report also highlights", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sana/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T03:11:10", "published_display": "17 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. Stock 12\u2011Month Price Target Cut to $9.14, Implies 230% Upside", "summary": "Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite t", "url": "https://www.tradingview.com/news/tradingview:f1247d43c5da9:0-sana-biotechnology-inc-stock-12-month-price-target-cut-to-9-14-implies-230-upside/", "source_name": "TradingView", "published_at": "2026-06-12T04:09:58", "published_display": "12 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRWhPOW0xdEdkeEhNZ09lYmxiZlNIbms1VTd4OWRGZDgxaEVjaHB3QmdhaWlPdEFFb0xVM3J2WC1uZjdKN2x5VmdBZkZNekFpWFVNT2lfQXRnUE1ER3hFZFhIZHdOSGJ2dTNzVDJndGhGcUhnblBxSElMTzJ6NC10VF9GTWc5VzNkZDVrVzJXSnhSSXhEaElXeEt1YzdaSlktbnczUHB3Ri1IYWVidW92QjJ6S2thRFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOdUpPZWNvYXN4YVVVVmNybHNKS1ljYTQ1SGQ2MVhNcFBFWnRZOWJjVk5HX1llWlFHLW5wak5xNGlZelJ4cVdIOUpObG84dEg3dUlTYS13WHlKTVlLUlZHZ3pTUGpzTGJ2bF95MnVsYWUtSHRHYm1FeUdhS01TTkZXOG1sdUtOaUJCWHQ1RWVpNnlkOXZRa2Y5NXBSZ0V3YUlyQnhmVkxITVJaVVpKdDU5bGllMEc0TThjMGJDX0hNbWdfUGpyaDJzZlpYVWZVTW1BbDNTcjZKcW5fQQ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology to Present at June 2026 Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sana-biotechnology-present-june-2026-200500258.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Raises $69 Million Through ATM Equity Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sana-biotechnology-raises-69-million-134304552.html", "source_name": "MT Newswires", "published_at": "2026-05-15T13:43:04+00:00", "published_display": "15 May 2026 13:43", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology raises $69 million through stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNlhRTk1tR29ZalZkWkZocTA3MVhYZVNrM0dtOEFkNk1EeEVkZG9mcXAtRklWWWhTeHU1ZDNsTlI0Q3FNamQ1ODdfYWZLczlwRVJFTGE3U1ZnZjhwR3hOWkZYTnlEUTRaTWVIcmtnaDViUmhlODhScXhMYkVnSHB5OE91dWNONTRxcTJfSXRnTlpXWEhDZjVWa1JzUlZsN0hSVDlMR0NrcURTcFJCMHFtcXln?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQ3hjSnZ3OGtsTGFXUndMQXM2MUwwdERzenUwbTVLRE0teFdRcktqYUVUZFVJWmZ5aEdlenNDaFBtdUVQcXFHaVdvRkZDVjJhNzZmSlJiWWFBbXpaenJiUGZTM0lfenF0UE1BM2I4VWFWcS1xTFdkblc0XzBDSTBYaWRKUlpUWFRzNWRfeDVjRVhUakxXT1lNVElTdWFBVkRDSWRjdk1ZWXUwaFdVakVjWFBmYURteGs?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs", "summary": "", "url": "https://finance.yahoo.com/news/sana-biotechnology-presents-preclinical-data-200500344.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNR25OTVdZcDQ2Q2lKd1l2bGtxM3AtU0J0cHBGMEVGQ1pKa2hGQV9VRWx4dk0zVjhhZ2NfWjhhcUNnQWstNllCQjRFbHVPbENkSEV4eE9ReHJTczNndEJFU3NqemhlNUFqZHRITHFGQjFEX3JIOTFVSHRtODhfcEpodTIyUVMtMVNyT1l3MUxJUkpaekVvSjJ2bEJFNlY4Y2FvMndMcnZLLXFzTzhadXVUalM5Vmk3YTI4VU5Mc2hMTkFXSEtnRDZEOFhKcUZiX01adlc2TEo2UFdZeENfSE5wNWMtQ3ljRlVZVURLUw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNSjJERjAwcGFXcFhCUEtlU2E4ckt1R0FrNGotX0I3U2JpaEpycmFsSkkyamlpMlZuVDRZX1U0V1FWaThFSnpyVmc4TnJsS1pSbGpqZGZ0dlctdGpaeW5mcUVsbWRTU2JTMWNxMUdLUWc4b1dMd3NlUmNlWWhVZTBxUXdUN0txWXJIN2VIWldsVEdWd3J2VVNhalFKcDh3NHZCRmZhdHRjMmpRSDg3NERyTEZvVmNPbXVXSVJFRlZ2bE9RWWVpQnlFM09VMzBqMFRGNXZ5cGl2ck1JZjhTVHBjVDc3b1k5SGfSAewBQVVfeXFMTzBPMzVYcG1nMzBNV2J2Tnl2NXphcDhJeHRYdnZhQWR2RVhDRGpyRmRUcXFSa2cyMEl1aTFubFI2b1FINnFGR0JsQVduQl9JMlNGQ2ZaQWdtWmZTM1hYTnRVaGZLYnVZT1lTS192ODJ1THRUZndqU3R3d2RJMXZVLWdvTkJwVVVmTVFRSjhLR3puX1FFaktqdVJYeDd3S1R0ZFJiZS0wOHhkSDlOQ3NhaGxac3YwbDZLYlBRRG1SR1BsRWl4ek1fcXd3ckQ4cFZVcU1QT1N2WFltTlhlVktQUmhudWt3MEh3SEVOSWw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdlhvZ3NGaUg5dnFNa1FOMy04TmpmajV5VC02MDI1M3RrVjQ4MFM4ZjgzVjRNRXlCSEJZYi1GUkNVb0VpX005OTVDMm1VUWUtNC02akpTVTF4Z2dJaTlsUFV1Vm9LeHNBMjJfSHpXVFg4Tm5aY3k1Q2xicy1aeVpiVDBMMXlCMkN5cUpoWlM0OEdBRDJQTEwwbUx6dG5OSC1MNFhuRVVleVBYak1i?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUElycm5CalZNcEJFcXYyYnNkQmVMRU1vaWhDRWtOYlhpX3R4T1pSakZReWdLOFJYZnN5WmJJd2ctUF9IQWs1V2thQXFFRFJNNzlsTkJVeXNRd2FxOGxOVlA3NWVxUVRfVkRLMllMbU0xYWpHaHpIa014X3pWZ3dObDlsaDdQVlRaSGZnWFZPRDJNNU1TSVBNeVppb0FHRmxReWc?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u200bSana Biotechnology Inc. (SANA) Hits New Milestone on Cell Therapy for Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxORlZWYTE3NzFOS1l0UUR1QVNyeE5sdUpTV0p3RkpYS2QyNGVWc0djb1hPTFpQMERwNHBFaGhoRW1wSHA1c1k2R29EVTM0R3kzQnVmWHpSZVRDUXh2YWFYVDJyUDZsa09hUEVNbGZyQ0ZrYTlCeGFUeC1RZ1Y3Tm9JeEpBMDJSTFFqOHZFWkx4dlkxWnRxWVcwVkN3UTJoZGd0RU5j?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to the latest disclosure filed with the US Securities and Exchange Commission, the biotechnology company Sana Biotechnology, Inc. has completed a significant equity transaction.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTFBEMDlkOW9rODE3enAxbXJfUlNZbHQ2ZjF3dDF2Y2R3OWptZjQ2RTNjeDc4OGNSMS14Q3BtRFUyclNHVWsyYnZUbkN4Rzh3OWZqa2I0eFlSMjlKRVZwOHfSAWNBVV95cUxONjk4aGxrbHhLQjhhVVJDdkFKNndsMFlDOVNLbTFVbzd1OEFiRlE4T2YzWmZOa0xGbjFsLWlvclN4R29BX2hoWDdBWWw0MFpZaUtYQUloZDFZNUF2ODVXMTRFZlk?oc=5", "source_name": "Bitget", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxObjd3eF9NUlotekVmNGRYUnp0dWpMWmpacG5LSzFQS2hjUmFGc3o0Vnc0SkVLOHNRek5ncnJyX0M0QTY2VTdRdUtNQk9PdE1mSE0zYlVRRzZ2QTZtckk5dHdERVpzQnlpLWNQTVhzVVlqYTBNZ0N5ZE9lX290djJnMTFYT0k?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/sana-biotechnology-sana-publishes-14-211145927.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T21:11:45+00:00", "published_display": "16 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-16T05:52:27+00:00", "published_display": "16 Jul 2026 05:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in Focus - Tick Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPbU9EZjJmVzlzWENWTFdnOWZxS1VpQUN0S1dPYTUyNjRfdUZSUG1ORXp4VFdOa2djaGd5RHlWWHVoTndPZDdycXlBWmdQaDV0R0JsWFRQTDFuc1kwbTIxOEJ2UUg2Rzl0cVNVdkRDMjRRNWVCb1I5cjU3aWdUOUVIR0I1aW01MUx3aU5udXdqc0R0UGVsc2Q3QmRRZ1Z1TFMxakxESlhvWDY3SGNweWtsUW9wSVAydVNmOGtLZERKdTNZSllvNUpveWxCNk5JQkZHbGdnbg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-15T16:40:15+00:00", "published_display": "15 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes", "summary": "Sana Biotechnology announced a follow-on publication in The New England Journal of Medicine (NEJM) detailing 14-month follow-up data from an investigator-sponsored study of UP421, a hypoimmune-modified islet cell therapy for Type 1 Diabetes. The data reinforces that HIP-modified ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326134/0/en/sana-biotechnology-announces-follow-on-publication-in-the-new-england-journal-of-medicine-nejm-highlighting-groundbreaking-long-term-data-and-durability-of-hypoimmune-modified-isle.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T22:11:59", "published_display": "13 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Morgan Stanley 23rd Annual Global Healthcare Conference summary", "summary": "Sana Biotechnology (SANA) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, outlining its strategic vision to revolutionize medicine through gene and cell-based therapies, specifically targeting allogeneic transplant rejection and precise genetic repair. T", "url": "https://quartr.com/events/sana-biotechnology-inc-sana-morgan-stanley-23rd-annual-global-healthcare-conference_FkPpRoH0", "source_name": "Quartr", "published_at": "2026-07-08T21:10:48", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary", "summary": "Sana Biotechnology presented key scientific advances and clinical data at the 43rd Annual J.P. Morgan Healthcare Conference 2025, highlighting the first successful transplant of gene-edited allogeneic islet cells in a type 1 diabetes patient without immunosuppression. The company", "url": "https://quartr.com/events/sana-biotechnology-inc-sana-43rd-annual-j-p-morgan-healthcare-conference-2025_FkPpRpPu", "source_name": "Quartr", "published_at": "2026-07-08T21:10:48", "published_display": "08 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed", "summary": "Sana Biotechnology (SANA) was recently removed from several Russell value benchmarks, including the Russell 3000 Value and Russell 2000 Value indexes. This removal impacts how index funds and institutional investors view the stock, but it doesn't change the company's scientific o", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sana/sana-biotechnology/news/sana-biotechnology-sana-is-up-181-after-removal-from-key-rus", "source_name": "Simply Wall Street", "published_at": "2026-07-08T20:07:13", "published_display": "08 Jul 2026 20:07", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotech heads to EASD with diabetes cell therapy update", "summary": "Sana Biotechnology will present clinical findings from its first-in-human study of UP421 at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This experimental cell therapy is designed to make transplanted insulin-producing cells \"hidden\" from the imm", "url": "https://longevity.technology/news/sana-biotech-heads-to-easd-with-diabetes-cell-therapy-update/", "source_name": "Longevity.Technology", "published_at": "2026-07-08T14:39:13", "published_display": "08 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Bank of America Global Healthcare Conference 2026 Summary", "summary": "Sana Biotechnology (SANA) delivered a summary at the Bank of America Global Healthcare Conference 2026, highlighting its dual strategic focus on engineering cells both ex vivo (for cell replacement in Type 1 diabetes) and in vivo (for cell repair/signaling change in CAR-T therapy", "url": "https://quartr.com/events/sana-biotechnology-sana-bank-of-america-global-healthcare-conference-2026_FkPpTd0w", "source_name": "Quartr", "published_at": "2026-07-08T08:41:05", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar", "summary": "This document from Sana Biotechnology details a Statement of changes in beneficial ownership of securities for Director Bishop Hans Edgar. The filing is a routine disclosure of insider transactions as required by the SEC.", "url": "https://www.moomoo.com/news/notice/307681675/sana-biotechnology-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-08T04:11:24", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Sana Biotechnology Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Sana Biotechnology Inc. on July 7, 2026, as published by Investing.com. It is a brief announcement indicating an insider transaction or change in beneficial ownership for the company. The article contains minimal detail beyond the initi", "url": "https://ng.investing.com/news/stock-market-news/form-4-sana-biotechnology-inc-for-7-july-93CH-2589772", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T20:39:13", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares", "summary": "Sana Biotechnology director Hans Edgar Bishop received 6,297 fully vested restricted stock units (RSUs) as a compensation-related grant, increasing his direct holdings to 5,854,800 shares. The Form 4 filing indicates this was a stock grant at a price of $0.00 per share, not an op", "url": "https://www.stocktitan.net/sec-filings/SANA/form-4-sana-biotechnology-inc-insider-trading-activity-750821490b89.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:24", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative?", "summary": "Sana Biotechnology (SANA) was recently removed from several Russell value-oriented benchmarks, including the Russell 2000, which could impact its institutional investor base and liquidity. Despite potential short-term pressure, the article suggests that the company's clinical mil", "url": "https://www.sahmcapital.com/news/content/will-removal-from-russell-value-benchmarks-change-sana-biotechnologys-sana-institutional-investor-narrative-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-03T07:39:35", "published_display": "03 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025", "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ:SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana made false statements and concealed risks regarding its financial ca", "url": "https://www.natlawreview.com/press-releases/sana-lawsuit-alert-levi-korsinsky-notifies-sana-biotechnology-inc-0", "source_name": "The National Law Review", "published_at": "2026-07-02T18:41:21", "published_display": "02 Jul 2026 18:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026", "summary": "Sana Biotechnology will present clinical data at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight results from a first-in-human study of UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune", "url": "https://finance.yahoo.com/healthcare/articles/sana-biotechnology-announces-symposium-presentation-130000389.html", "source_name": "Market source", "published_at": "2026-07-02T07:41:25", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana to show first-in-human islet transplant data without immunosuppression", "summary": "Sana Biotechnology (NASDAQ: SANA) is set to present clinical data on UP421, an allogeneic primary islet cell therapy utilizing its hypoimmune platform, at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. This first-in-human transplant data for type 1", "url": "https://www.stocktitan.net/news/SANA/sana-biotechnology-announces-symposium-presentation-at-the-european-u6x9m1r88pgo.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:40:43", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Symposium Presentation at the", "summary": "Sana Biotechnology, Inc. (NASDAQ: SANA) announced a symposium presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The presentation will highlight clinical data from a first-in-human study of UP421, an allogeneic primary islet cell therap", "url": "https://www.globenewswire.com/news-release/2026/07/01/3320655/0/en/sana-biotechnology-announces-symposium-presentation-at-the-european-association-for-the-study-of-diabetes-easd-annual-meeting-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-01T12:40:33", "published_display": "01 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Sana Biotechnology stock rating on IND filing", "summary": "Citizens has reiterated a Market Outperform rating and an $8.00 price target for Sana Biotechnology (NASDAQ:SANA) following the company's plans to file an Investigational New Drug application for SG293, their first fusogen-based in vivo CAR-T program. Although the stock currently", "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-sana-biotechnology-stock-rating-on-ind-filing-93CH-4769771", "source_name": "Investing.com", "published_at": "2026-07-01T09:40:33", "published_display": "01 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark", "summary": "Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 3000 Value Benchmark. This news follows several other index removals for the company, including the Russell Small Cap Comp Value Benchmark, Russell 2500 Value Benchmark, and Russell 2000 Value Benchmark. ", "url": "https://www.marketscreener.com/news/sana-biotechnology-inc-nasdaqgs-sana-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8cf320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:10:21", "published_display": "29 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark", "summary": "Sana Biotechnology, Inc. (NasdaqGS: SANA) has been removed from the Russell 2500 Value Benchmark. This news comes amidst several other recent announcements regarding the company's removal from various Russell indices and presentations at healthcare conferences, as well as an equi", "url": "https://www.marketscreener.com/news/sana-biotechnology-inc-nasdaqgs-sana-dropped-from-russell-2500-value-benchmark-ce7f5fdcd88fff20", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:10:44", "published_display": "29 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025", "summary": "Levi & Korsinsky, LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) seeking to recover losses for shareholders who purchased shares between March 17, 2023, and November 4, 2024. The lawsuit alleges that Sana Biotechnology made false s", "url": "https://natlawreview.com/press-releases/join-class-action-recover-losses-sana-biotechnology-inc-sana-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-28T05:10:44", "published_display": "28 Jun 2026 05:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) for alleged securities fraud between March 17, 2023, and November 4, 2024. The lawsuit claims Sana overstated its financial capacity and the prospects of certain produ", "url": "https://natlawreview.com/press-releases/lost-money-sana-biotechnology-inc-sana-contact-levi-korsinsky-join-class", "source_name": "The National Law Review", "published_at": "2026-06-27T15:10:14", "published_display": "27 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sana Biotechnology, Inc. \u2013 NASDAQ:SANA", "summary": "This page from TradingView displays financial information for Sana Biotechnology, Inc. (NASDAQ: SANA), specifically focusing on its price-to-earnings forward metric. The content indicates that the company's market data is closed with no trades. The article is a financial data pag", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:10:14", "published_display": "27 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sana Biotechnology, Inc. \u2013 NASDAQ:SANA", "summary": "This article provides the enterprise value to EBIT forward for Sana Biotechnology, Inc. (NASDAQ: SANA). It presents financial data via TradingView, indicating no current trades and a closed market for the stock. The content primarily focuses on the financial metric for SANA.", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:46", "published_display": "27 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA)", "summary": "This article provides an overview of Sana Biotechnology, Inc. (NASDAQ:SANA)'s financial actuals and estimates. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and analyst forecasts for future price target", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:00", "published_display": "25 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SANA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Sana Biotechnology, Inc. (SANA) stock, including current price, analyst ratings, and historical performance. Analysts project a max estimate of $16.00 and a min estimate of $7.00 for SANA, with a current price of $3.26. The company's financials", "url": "https://www.tradingview.com/symbols/NASDAQ-SANA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:51", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Sana Biotechnology Inc's (SANA) dividends and stock splits. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock prices and market capit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sana/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T09:11:10", "published_display": "17 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Sana Biotechnology Inc (SANA), including analyst ratings, price targets, and EPS estimates. Based on 9 analysts, the stock has a \"Buy\" rating with a target price of $7.00, representing a significant upside. The report also highlights", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sana/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T03:11:10", "published_display": "17 Jun 2026 03:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. Stock 12\u2011Month Price Target Cut to $9.14, Implies 230% Upside", "summary": "Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite t", "url": "https://www.tradingview.com/news/tradingview:f1247d43c5da9:0-sana-biotechnology-inc-stock-12-month-price-target-cut-to-9-14-implies-230-upside/", "source_name": "TradingView", "published_at": "2026-06-12T04:09:58", "published_display": "12 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQRWhPOW0xdEdkeEhNZ09lYmxiZlNIbms1VTd4OWRGZDgxaEVjaHB3QmdhaWlPdEFFb0xVM3J2WC1uZjdKN2x5VmdBZkZNekFpWFVNT2lfQXRnUE1ER3hFZFhIZHdOSGJ2dTNzVDJndGhGcUhnblBxSElMTzJ6NC10VF9GTWc5VzNkZDVrVzJXSnhSSXhEaElXeEt1YzdaSlktbnczUHB3Ri1IYWVidW92QjJ6S2thRFU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOdUpPZWNvYXN4YVVVVmNybHNKS1ljYTQ1SGQ2MVhNcFBFWnRZOWJjVk5HX1llWlFHLW5wak5xNGlZelJ4cVdIOUpObG84dEg3dUlTYS13WHlKTVlLUlZHZ3pTUGpzTGJ2bF95MnVsYWUtSHRHYm1FeUdhS01TTkZXOG1sdUtOaUJCWHQ1RWVpNnlkOXZRa2Y5NXBSZ0V3YUlyQnhmVkxITVJaVVpKdDU5bGllMEc0TThjMGJDX0hNbWdfUGpyaDJzZlpYVWZVTW1BbDNTcjZKcW5fQQ?oc=5", "source_name": "Morningstar", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology to Present at June 2026 Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sana-biotechnology-present-june-2026-200500258.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T20:05:00+00:00", "published_display": "27 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Raises $69 Million Through ATM Equity Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sana-biotechnology-raises-69-million-134304552.html", "source_name": "MT Newswires", "published_at": "2026-05-15T13:43:04+00:00", "published_display": "15 May 2026 13:43", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology raises $69 million through stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNlhRTk1tR29ZalZkWkZocTA3MVhYZVNrM0dtOEFkNk1EeEVkZG9mcXAtRklWWWhTeHU1ZDNsTlI0Q3FNamQ1ODdfYWZLczlwRVJFTGE3U1ZnZjhwR3hOWkZYTnlEUTRaTWVIcmtnaDViUmhlODhScXhMYkVnSHB5OE91dWNONTRxcTJfSXRnTlpXWEhDZjVWa1JzUlZsN0hSVDlMR0NrcURTcFJCMHFtcXln?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNQ3hjSnZ3OGtsTGFXUndMQXM2MUwwdERzenUwbTVLRE0teFdRcktqYUVUZFVJWmZ5aEdlenNDaFBtdUVQcXFHaVdvRkZDVjJhNzZmSlJiWWFBbXpaenJiUGZTM0lfenF0UE1BM2I4VWFWcS1xTFdkblc0XzBDSTBYaWRKUlpUWFRzNWRfeDVjRVhUakxXT1lNVElTdWFBVkRDSWRjdk1ZWXUwaFdVakVjWFBmYURteGs?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOUTY4SzBROHBQYlRIT2Y0U2NWN1NHN0hlSkJHNXZMamhvN1dpRWVpNlZKb3I4UDAtOVZRS2dqNzRiTWZISUtTdlZVbldnZ3pfV1N0VXh0NWV0ckpMcUZGRDdaZGlXSEFZWktvdHVreUladmplcUJXLUpMYUxpMVBIOEJWSlJodnJhZjBHMlN6dF8zVUlRWHlHblFQZ3dNa1FWUDJ4eVVNMWVZZ0dVaWtsZEhBcTB2bFNROXE3VXFYQ3NJWXIxYjRYZw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS Biotechnology Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTXNUdVZadGlGUFRyY004aWwyQUQ1eUhVLVRxbUJtWTVrSndNdFV0S0xJYjdPTlhUVmNxVDl3Q2Y4VnE0d280bDh3QlFOOUNHS2JtRExnX0FfWHozeUNKVDhpRjJLbHZjdHdEQ0hldlRZbTFKdVNqWFEzRlFCbkNOclYweTJCcnNvXzFXWWVRWEhnSXVPbVJwSUJSbldKQlFXUF8zOTdKYlRxUQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs", "summary": "", "url": "https://finance.yahoo.com/news/sana-biotechnology-presents-preclinical-data-200500344.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNR25OTVdZcDQ2Q2lKd1l2bGtxM3AtU0J0cHBGMEVGQ1pKa2hGQV9VRWx4dk0zVjhhZ2NfWjhhcUNnQWstNllCQjRFbHVPbENkSEV4eE9ReHJTczNndEJFU3NqemhlNUFqZHRITHFGQjFEX3JIOTFVSHRtODhfcEpodTIyUVMtMVNyT1l3MUxJUkpaekVvSjJ2bEJFNlY4Y2FvMndMcnZLLXFzTzhadXVUalM5Vmk3YTI4VU5Mc2hMTkFXSEtnRDZEOFhKcUZiX01adlc2TEo2UFdZeENfSE5wNWMtQ3ljRlVZVURLUw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology (SANA) Valuation Check As Conference Update And Partnerships Keep Investor Focus High", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNdlhvZ3NGaUg5dnFNa1FOMy04TmpmajV5VC02MDI1M3RrVjQ4MFM4ZjgzVjRNRXlCSEJZYi1GUkNVb0VpX005OTVDMm1VUWUtNC02akpTVTF4Z2dJaTlsUFV1Vm9LeHNBMjJfSHpXVFg4Tm5aY3k1Q2xicy1aeVpiVDBMMXlCMkN5cUpoWlM0OEdBRDJQTEwwbUx6dG5OSC1MNFhuRVVleVBYak1i?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOUElycm5CalZNcEJFcXYyYnNkQmVMRU1vaWhDRWtOYlhpX3R4T1pSakZReWdLOFJYZnN5WmJJd2ctUF9IQWs1V2thQXFFRFJNNzlsTkJVeXNRd2FxOGxOVlA3NWVxUVRfVkRLMllMbU0xYWpHaHpIa014X3pWZ3dObDlsaDdQVlRaSGZnWFZPRDJNNU1TSVBNeVppb0FHRmxReWc?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "\u200bSana Biotechnology Inc. (SANA) Hits New Milestone on Cell Therapy for Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxORlZWYTE3NzFOS1l0UUR1QVNyeE5sdUpTV0p3RkpYS2QyNGVWc0djb1hPTFpQMERwNHBFaGhoRW1wSHA1c1k2R29EVTM0R3kzQnVmWHpSZVRDUXh2YWFYVDJyUDZsa09hUEVNbGZyQ0ZrYTlCeGFUeC1RZ1Y3Tm9JeEpBMDJSTFFqOHZFWkx4dlkxWnRxWVcwVkN3UTJoZGd0RU5j?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "According to the latest disclosure filed with the US Securities and Exchange Commission, the biotechnology company Sana Biotechnology, Inc. has completed a significant equity transaction.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXkFVX3lxTFBEMDlkOW9rODE3enAxbXJfUlNZbHQ2ZjF3dDF2Y2R3OWptZjQ2RTNjeDc4OGNSMS14Q3BtRFUyclNHVWsyYnZUbkN4Rzh3OWZqa2I0eFlSMjlKRVZwOHfSAWNBVV95cUxONjk4aGxrbHhLQjhhVVJDdkFKNndsMFlDOVNLbTFVbzd1OEFiRlE4T2YzWmZOa0xGbjFsLWlvclN4R29BX2hoWDdBWWw0MFpZaUtYQUloZDFZNUF2ODVXMTRFZlk?oc=5", "source_name": "Bitget", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxObjd3eF9NUlotekVmNGRYUnp0dWpMWmpacG5LSzFQS2hjUmFGc3o0Vnc0SkVLOHNRek5ncnJyX0M0QTY2VTdRdUtNQk9PdE1mSE0zYlVRRzZ2QTZtckk5dHdERVpzQnlpLWNQTVhzVVlqYTBNZ0N5ZE9lX290djJnMTFYT0k?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 100, "total_relevant": 65, "sentiment_summary": {"positive": 18, "negative": 11, "neutral": 36, "score": 53, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 19.95, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 12.1, "count": 22}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 3.85, "latest_week": "2026-07-10", "one_week_move": -4.0, "four_week_move": 43.7, "twelve_week_move": 9.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.698543, "market_dynamics_buy_signal": false, "relative_strength": -13.640476, "fair_value_gap": -11.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.6383, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, +43.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 8}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "The National Law Review", "count": 3}, {"label": "Investing.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 65}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 22}, {"label": "Regulatory and legal", "count": 3}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "65", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.0% over one week, +43.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM"}], "updated_at": "2026-07-17T06:25:27.306823+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}